Brief: Intellia Therapeutics Q4 Net Income USD -95.786 Million
26/02/2026 12:30
Feb 26 (Reuters) - Intellia Therapeutics Q4 operating expenses USD 121.727 million. Q4 collaboration revenue USD 23.017 million Q4 operating income USD -98.71 million Q4 basic EPS USD -0.83
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)